Αρχική World News Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive Early...

Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive Early Breast Cancer

Long-term findings presented at the ESMO Breast Cancer Virtual Congress 2021, held 5 to 8 May, showed that similar disease-free survival (DFS) benefit was obtained with 9 weeks versus one-year of adjuvant trastuzumab in patients with HER2-positive early breast cancer and low to intermediate risk for disease recurrence, which may reassure patients who must discontinue adjuvant trastuzumab earlier than one year due to cardiac adverse events.

Prof. Pier Franco Conte of the Department of Surgery, Oncology and Gastroenterology, University of Padova in Padova, Italy presented long-term data from the ShortHER study (EUDRACT 2007-004326-25; NCT00629278) regarding the co-primary endpoint of overall survival (OS) as well as updated DFS curves. DFS was evaluated according to hormone receptor status and 3 risk categories: low risk (defined as pT< 2cm and pN0), intermediate risk (pT < 2cm and 1-3 pN+ or pT > 2cm and 0-3 pN+), and high risk (any pT and 4+ pN+).

Previous reports described the design, patient characteristics, and event-driven DFS analysis of the study, which was designed to demonstrate the non-inferiority of short versus long administration of adjuvant trastuzumab. However, at the event driven analysis, the hazard ratio (HR) for DFS was 1.13 (90% confidence interval [CI] 0.89-1.42), which did not meet the non-inferiority margin of DFS < 1.29.1

In ShortHER, 1254 patients with HER2-positive early breast cancer were randomly assigned to chemotherapy followed by either 9 weeks (short arm n=626) or one year (long arm n=627) of adjuvant trastuzumab.

With median follow-up of 8.7 years, 121 DFS events occurred with 9 weeks of treatment compared to 116 with one year of adjuvant trastuzumab (HR 1.09; 90% CI 0.88-1.35).

DFS was similar with 9 weeks and one-year of trastuzumab in patients with low and intermediate risk

The evaluation according to post-hoc risk groups demonstrated in 37.2% of the study population that was at low risk HR for DFS of 0.91 (90% CI 0.60-1.38), in intermediate risk patients which comprised 46.7% of the study population HR 0.88 (90% CI 0.63-1.21), and in high risk patients (15.2% of the study population) HR 2.06 (90% CI 1.36-3.13) with short versus long treatment duration of trastuzumab.

Regarding DFS per hormone receptor status, in hormone receptor positive patients receiving the short and long treatment HR 1.11 (90% CI 0.85-1.46) compared to HR 1.06 (90% CI 0.75-1.50) in hormone receptor negative patients.

A total of 109 deaths were reported representing 58 with the short treatment, and 51 with the one-year trastuzumab treatment. In the respective arms, the 9-year OS was 90% with short versus 91% with one-year of trastuzumab (HR 1.18; 90% CI 0.86-1.62).

Dr. Evandro de Azambuja of the Jules Bordet Institute in Brussels, Belgium who discussed the study findings said that short duration is less cardiotoxic, but one-year trastuzumab remains the standard at the present. Nevertheless, a shorter trastuzumab administration could be an option to be tested in patients with a low risk of relapse or to reassure patients who experience cardiac events before the end of therapy. However, low risk patients have been de-escalated on chemotherapy (APT trial). Intermediate risk includes N1-3, and those patients benefit from dual blockade with pertuzumab plus trastuzumab. Short regimen can facilitate the access to trastuzumab to patients with low risk of relapse living in countries with limited resources. He suggested food for thoughts: combining pathologic features with biomarkers to identify these patients who could benefit from this de-escalated strategy. 


The investigators stated that the updated DFS and OS analysis of the ShortHER study confirms the favourable long term results obtained with 9 weeks of adjuvant trastuzumab in the patients with low and intermediate risk factors who represented the majority (83.9%) of the ShortHER study population and reflect most of the patients treated in daily practice.

Although one year of trastuzumab remains standard for adjuvant therapy, the authors recommend that these findings suggest that a shorter trastuzumab administration could be an option in the case of limited access to trastuzumab.

They concluded that their data are also reassuring for patients who have to discontinue trastuzumab due to a decline in left ventricular ejection fraction.

The study was funded by the Agenzia Italiana del Farmaco (AIFA).


1. Conte P, Frassoldati A, Bisagni G et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Annals of Oncology 2018;29(12):2328-2333. doi: 10.1093/annonc/mdy414.


41O – Conte PF, Frassoldati A, Bisagni G, et al. Nine weeks vs 1 year adjuvant trastuzumab: long term outcomes of the ShortHER randomised trial. ESMO Breast Cancer Virtual Congress 2021 (5-8 May).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

10 Ways You Can Nurture A More Sustainable Garden

Sustainable gardening doesn’t have a firm, technical definition. It’s the concept of using sustainable gardening techniques that not only cause no harm to the...

Cancer Research UK spin-out gets US approval to trial unique T cell therapy

Cancer Research UK’s spin-out, GammaDelta Therapeutics (‘GammaDelta’), has been given approval from the US Food and Drug Administration (FDA) to trial its unique T-cell...

Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy

The ECOG-ACRIN EA1131 study hypothesised that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype triple-negative breast cancer...

Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit [ESMO Virtual Plenary Press Release]

VP6-2021 - IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk,...

Breaking News: Supreme Court Upholds the Affordable Care Act

It’s a great day for cancer survivors. The Supreme Court of the United States (SCOTUS) upheld the Affordable Care Act (ACA), commonly known as...

How Does CAR T-Cell Therapy Work in Treating Cancer?

Craig A. Portell, MD, is an Associate Professor of Medicine at the University of Virginia and a member of the UVA Cancer Center in...